Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
antiangiogenic drugs as a targeted drug therapy
Transcript of antiangiogenic drugs as a targeted drug therapy
Angiogenesis and cancer
side effects and resistance
what is Angiogenesis?
A new blood vessel is coming to be created
Angiogenesis and Cancer
DID we make it ?
Yes we did.
Wounds that don't heal
so,we can target cancer cell from this point
Antiangiogenic Drugs as a Targeted Drug Therapy
to be more specific: :
Creating new blood vessel is done by two mechanisms:
de novo synthesis of blood vessels
creation of new vessels from already existing vessels.
when do we need it?
female reproductive system
(wound healing and tumor growth)
VEGF + PDGF
a tumor needs an independent blood supply, which is acquired by the expression of growth factors that recruit new vasculature from existing blood vessels
tumor growth and metastasis is angiogenesis-dependent
excessive production of angiogenic growth factors
excessive expression of their receptors
Tyrosine kinase receptor
The goal of their use:
a) therapeutic goal
synergistic effect with other drugs
b) protective goal
decrease systemic side effects
improve patients' quality of life
classification of antiangiogenic drugs
1-vascular endothelial growth factor receptor (VEGFR) inhibitors:
a) Tyrosine kinase and multi-kinase inhibitors:
b) Monoclonal antibodies
2-inhibitors of endothelial cell proliferation.
monoclonal antibody against VEGF
FDA Approved for:
1st angiogenesis inhibitor that was
slow tumor growth
extend the lives of patients.
Recurrent glioblastoma - alone
NSCLC - with carboplatin and paclitaxel
Metastatic Kidney cancer - with interferon alfa
Advanced Cervical cancer - with paclitaxel and cisplatin
small molecular inhibitor of several tyrosine protein kinases including:
Raf, MEK, ERK
advanced kidney cancer
advanced liver cancer
I-resistant thyroid cancer
and most important:
TKIs against the ABL family:
and much more
Did our bodies accept these drugs?
Take care if you are:
breast feeding mother
How did cancer deal with these drugs?
there is a must to develop a new class of drugs that inhibit the mutant VEGF and its receptor, and not the normal wild types, and to target the escaping mechanisms of the cancer.